Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01437852
Other study ID # STRATA2011
Secondary ID WFUHS 40269
Status Completed
Phase Phase 1
First received
Last updated
Start date September 2011
Est. completion date October 2014

Study information

Verified date December 2018
Source Mallinckrodt
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proposed study is designed as a phase Ib open-label, dose-escalation, multicenter study evaluating the safety, tolerability, and efficacy of StrataGraft skin tissue in promoting the healing of the deep partial-thickness component of complex skin defects. The proposed study population will include patients with 3-49% Total Body Surface Area (TBSA) complex skin defects including a deep partial-thickness component resulting from thermal injury. The study has been designed to focus on the evaluation of safety and tolerability of prolonged exposure to increasing amounts of a single application of StrataGraft skin tissue, while also assessing the potential for StrataGraft tissue to promote healing of the deep partial-thickness component of these complex skin defects as an alternative to donor site harvesting and autografting. Targeted enrollment for this study is up to 30 patients with complex skin defects due to thermal burns which require surgical excision and autografting. Subjects will be sequentially enrolled in two cohorts of increasing treatment area receiving StrataGraft skin tissue that has been stored refrigerated prior to clinical use. A third cohort will receive StrataGraft skin tissue which has been stored cryopreserved and thawed in the operating room just prior to grafting.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date October 2014
Est. primary completion date January 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Men and women aged 18-65 years, inclusive

- Written informed consent

- Sufficient healthy skin identified and designated as a donor site in the event that the StrataGraft treatment site requires autografting

- Complex skin defects of 3-49% TBSA requiring excision and autografting

- Total burn may consist of more than one wound area

- Deep partial-thickness thermal burn(s) with total area of 88 to 880 cm2 requiring excision and autografting

- First excision and grafting of treatment sites

Exclusion Criteria:

- Pregnant women and prisoners

- Patients receiving systemic immunosuppressive therapy

- Patients with a known history of malignancy

- Preadmission insulin-dependent diabetic patients

- Patients with concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives

- Expected survival of less than three months

- Participation in the treatment group of an interventional study within preceding 90 days prior to enrollment

- Full-thickness burns will be excluded as treatment sites

- Chronic wounds will be excluded as treatment sites

- The face, head, neck, hands, feet, buttocks, and areas over joints will be excluded as treatment sites

- Treatment sites adjacent to unexcised eschar

- Clinical suspicion of burn wound infection at the anticipated treatment sites

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
StrataGraft Skin Tissue


Locations

Country Name City State
United States University of Colorado Hospital Burn Center Aurora Colorado
United States UT-Southwestern Medical Center Dallas Texas
United States U.S. Army Institute of Surgical Research Fort Sam Houston Texas
United States University of Wisconsin Hospital Madison Wisconsin
United States Maricopa Integrated Health Systems, Arizona Burn Center Phoenix Arizona
United States Wake Forest University Baptist Medical Center Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Stratatech, a Mallinckrodt Company

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Wound Closure of the Treatment Sites at Three Months Determination of complete wound closure of both treatment sites was evaluated at 3 months. 3 months
Primary Percent Area of the StrataGraft Treatment Site Requiring Autografting by Day 28 The percentage of the treatment site area initially covered with StrataGraft tissue that required autograft by day 28 was determined. 28 days
See also
  Status Clinical Trial Phase
Completed NCT05023135 - DeepView SnapShot Portable (DV-SSP): Device Training Study
Completed NCT05276869 - Reliability and Feasibility of WeeFIM Instrument to Measure Functional Independence in Pediatric Burns
Completed NCT04548635 - VR for Burn Dressing Changes at Home Phase 2/Phase 3
Not yet recruiting NCT06076031 - Effects of Applying Streaming Media on Reducing Pain in Patient With Second-degree Burn During Changing Dressing N/A
Recruiting NCT05084248 - Vitamin D Deficiency in Adults Following a Major Burn Injury Phase 4
Completed NCT03113253 - TRANexamic Acid to Reduce Bleeding in BURN Surgery Phase 4
Recruiting NCT04090424 - Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT03159182 - Study of Silicone Material Inserts To Treat Burn Scars N/A
Recruiting NCT02904941 - Human Amniotic Versus Synthetic Membrane as a Transient Skin Cover for Pediatric Burns N/A
Completed NCT02681757 - Comparison of Mepitel Ag vs Antibiotic Ointment Used With Soft Cast Technique for Treatment of Pediatric Burns N/A
Recruiting NCT01812941 - Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients N/A
Completed NCT01214811 - Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing Phase 3
Completed NCT01061502 - Efficacy Study of a Bioelectric Dressing to Treat Skin Graft Donor Site Wounds Phase 1/Phase 2
Terminated NCT00822796 - Thermogard™ Efficacy Trial N/A
Terminated NCT00634166 - Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group Phase 4
Terminated NCT00824681 - Effect of Music Therapy on Families of Burn Patients Phase 1
Terminated NCT00464386 - Continuous Glucose Monitoring (POC) in the ICU N/A
Withdrawn NCT00216983 - Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding N/A
Recruiting NCT03992547 - The Effects of Robot-assisted Gait Training(RAGT) On Patients With Burn N/A